Merit Medical Systems MMSI
- Market cap
- $5.6B
- PE
- 38.6×
- 10y median 57.5×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.5×
- EV/EBIT
- 28.6×
- Revenue, 12 months
- $1.6B
- +10% on a year ago
- Net margin
- 9.2%
- Free cash flow yield
- 3.6%
Merit Medical Systems trades at 38.6× trailing earnings, cheaper than 92% of the last ten years. Revenue was $1.6B over the last twelve months, up 10% on a year earlier with a 9% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $315.2M+10% | $324.5M+11% | $323.5M+9% | $338M+6% | $339.8M+8% | $355.2M+9% | $355.4M+10% | $382.5M+13% | $384.2M+13% | $393.9M+11% | $381.9M+8% | $418.8M+10% | |
| Cost of revenue | $173M+9% | $174M+10% | $171.8M+8% | $176.9M+6% | $182.3M+5% | $182.2M+5% | $183.3M+7% | $198M+12% | $197.7M+9% | $198.6M+9% | $197.1M+8% | $203.7M+3% |
| Gross profit | $142.2M+11% | $150.5M+12% | $151.7M+10% | $161.1M+5% | $157.5M+11% | $173M+15% | $172M+13% | $184.5M+15% | $186.4M+18% | $195.4M+13% | $184.8M+7% | $215.2M+17% |
| R&D | $19.6M+2% | $21.6M+6% | $21.5M+1% | $20.3M+1% | $20.5M+5% | $25.2M+16% | $22.5M+5% | $24.4M+20% | $24M+17% | $26.5M+5% | $22.6M+1% | $25.4M+4% |
| SG&A | $86.9M−3% | $95.8M+15% | $94.4M+5% | $94.6M−6% | $99.6M+15% | $111.1M+16% | $107.5M+14% | $113.1M+20% | $119.8M+20% | $114.8M+3% | $118.2M+10% | $129.2M+14% |
| $35.1M+88% | $33.6M+11% | $35.9M+36% | $45.9M+60% | $37.3M+6% | $36.6M+9% | $41M+14% | $46.9M+2% | $42.6M+14% | $54.2M+48% | $44.2M+8% | $60.4M+29% | |
| Interest expense | $4.8M+164% | $5M+131% | $8M+300% | $7.7M+109% | $7.5M+55% | $8M+61% | $6.6M−18% | $6.8M−12% | $6.8M−10% | $6.4M−20% | $6.5M−1% | $12.1M+79% |
| Pre-tax income | $30.2M+72% | $31.5M+4% | $34.3M+35% | $45.8M+84% | $36.7M+21% | $33.1M+5% | $38M+11% | $43.4M−5% | $38.5M+5% | $51.1M+54% | $53.5M+41% | $51.3M+18% |
| $4.4M+88% | $3.8M | $6.1M+27% | $10.1M+117% | $8.2M+87% | $5.2M+35% | $7.8M+28% | $10.8M+7% | $10.8M+31% | $13.1M+151% | $12.6M+61% | $12.5M+16% | |
| Net income | $25.8M+69% | $27.6M−17% | $28.2M+36% | $35.7M+77% | $28.4M+10% | $27.9M+1% | $30.1M+7% | $32.6M−9% | $27.8M−2% | $38M+36% | $41M+36% | $38.8M+19% |
| $0.44+63% | $0.47−19% | $0.48+33% | $0.61+74% | $0.48+9% | $0.46−2% | $0.49+2% | $0.54−12% | $0.46−4% | $0.63+37% | $0.68+39% | $0.65+20% | |
| 58.4M+1% | 58.4M+1% | 58.6M+1% | 58.7M+1% | 59.5M+2% | 60.6M+4% | 61.3M+5% | 60.6M+3% | 59.9M+1% | 60M−1% | 60M−2% | 60M−1% |
EPS, diluted: 10 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 15 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY19: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Merit Medical Systems' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MMSIMerit Medical Systems | $5.6B | 38.6× | 57.5× | 3.5× | +10% | 9.2% | |
| HAEHaemonetics | $5.4B | 58.1× | 51.6× | 4.0× | +0% | 7.1% | |
| VNTVontier | $4.6B | 14.3× | 13.5× | 1.5× | +1% | 11.3% | |
| MSAMSA Safety | $7B | 22.7× | 36.3× | 3.6× | +6% | 16.1% | |
| BMIBadger Meter | $4.4B | 35.3× | 47.6× | 5.0× | −2% | 14.3% | |
| ICUIICU Medical | $4.2B | 141× | 57.8× | 1.9× | −9% | 1.4% | |
| NVSTEnvista | $3.8B | 40.7× | 27.9× | 1.3× | +12% | 3.3% | |
| WRBYWarby Parker | $3.2B | 370× | 366× | 3.5× | +11% | 0.8% | |
| PODDInsulet | $10.3B | 27.9× | 63.0× | 3.4× | +29% | 12.3% | |
| ATRCAtriCure | $3B | 281× | 58.4× | 5.3× | +14% | 1.9% | |
| GMEDGlobus Medical | $10.9B | 20.8× | 37.4× | 3.5× | +20% | 17.0% | |
| Peer median | $4.5B | 38.0× | 49.6× | 3.5× | +9% | 9.2% |
Investors who own it
Investors we follow who held Merit Medical Systems at the end of Jun 30, 2026, from their 13F filings.
- Lee AinslieMaverick Capital0.6% of portfolioadded
More on Merit Medical Systems
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .